recombinant human ifn-a2b  (ProSpec)

Journal: Cancer Science

Article Title: Interferon‐alpha modulates the chemosensitivity of CD 133‐expressing pancreatic cancer cells to gemcitabine

doi: 10.1111/j.1349-7006.2012.02235.x

Figure Lengend Snippet: Interferon‐alpha (IFN‐α) reduced the proportion of CD133+ cells in Capan‐1 cells. (A) Expressions of IFNAR 1 (left) and IFNAR 2 (right). (B) IFN‐α inhibited Capan‐1 cell growth in a dose‐dependent manner for 48 h exposure. (C) IFN‐α (5000 U/mL) treatment for 48 h decreased the proportion of CD133+ cells in Capan‐1 cells over time. (D) CD133 protein level analyzed by western blot. (E) IFN‐α‐dependent phosphorylation/activation of Mnk1 in a time‐dependent manner (left and right). (F) Mnk1 mediated the antiproliferative response to the co‐administration of IFN‐α and gemcitabine (GEM). Capan‐1 cells were treated in the combination of IFN‐α, GEM and Mnk1 inhibitor CGP57380. After 48 h incubation, cell viability was determined by MTT assay. These results are the means and SD of values from four wells in one representative experiment.

Article Snippet: GEM was supplied by Eli Lilly Japan (Tokyo, Japan), and recombinant human IFN‐α was purchased from Acris Antibodies GmbH (Herford, Germany).

Techniques: Western Blot, Activation Assay, Incubation, MTT Assay

Journal: Cancer Science

Article Title: Interferon‐alpha modulates the chemosensitivity of CD 133‐expressing pancreatic cancer cells to gemcitabine

doi: 10.1111/j.1349-7006.2012.02235.x

Figure Lengend Snippet: Interferon‐alpha (IFN‐α) contributes to combined chemotherapy by reducing the proportion of the G0/G1 phase cells and increasing the proportion of the S phase and apoptotic cells. (A) Comparison of G0/G1, S and apoptotic cells by BrdU assay between CD133+ and CD133− cells treated with gemcitabine (GEM) alone, IFN‐α alone or GEM + IFN‐α for 24 h. In CD133+ (upper) and CD133− (lower) populations, * vs **, * vs # and # vs ## indicate P < 0.01. Error bars indicate SD. (B) Model of IFN‐α modulating CD133+ cells from G0/G1 to the S phase and targeting them combined with GEM.

Article Snippet: GEM was supplied by Eli Lilly Japan (Tokyo, Japan), and recombinant human IFN‐α was purchased from Acris Antibodies GmbH (Herford, Germany).

Techniques: BrdU Staining

Journal: Cancer Science

Article Title: Interferon‐alpha modulates the chemosensitivity of CD 133‐expressing pancreatic cancer cells to gemcitabine

doi: 10.1111/j.1349-7006.2012.02235.x

Figure Lengend Snippet: Effect of interferon‐alpha (IFN‐α) on the growth of xenograft Capan‐1 tumor in nude mice. (A) Xenograft tumors with IFN‐α + gemcitabine (GEM) treatment were smaller than those with controls in nude mice. (B) Tumor growth curves of Capan‐1 xenografts which were treated with GEM (100 ng/mL) alone, IFN‐α (5000 U/mL) alone or GEM plus IFN‐α. IFN‐α + GEM treatment showed a significant effect (P < 0.01). (C) Comparison of histological CD133 expression in Capan‐1 xenografts with treatments at week 5 after inoculation into nude mice.

Article Snippet: GEM was supplied by Eli Lilly Japan (Tokyo, Japan), and recombinant human IFN‐α was purchased from Acris Antibodies GmbH (Herford, Germany).

Techniques: Expressing